[go: up one dir, main page]

WO2003053336A3 - Methods for the treatment of peripheral neural and vascular ailments - Google Patents

Methods for the treatment of peripheral neural and vascular ailments Download PDF

Info

Publication number
WO2003053336A3
WO2003053336A3 PCT/US2002/035654 US0235654W WO03053336A3 WO 2003053336 A3 WO2003053336 A3 WO 2003053336A3 US 0235654 W US0235654 W US 0235654W WO 03053336 A3 WO03053336 A3 WO 03053336A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
peripheral neural
ailments
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035654
Other languages
French (fr)
Other versions
WO2003053336A2 (en
Inventor
Richard A Rosenbloom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prophase Labs Inc
Original Assignee
Quigley Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/049297 external-priority patent/WO2002049575A2/en
Priority to AU2002352501A priority Critical patent/AU2002352501B2/en
Priority to CA002470603A priority patent/CA2470603A1/en
Priority to JP2003554096A priority patent/JP2005518381A/en
Priority to EP02789474A priority patent/EP1455778A4/en
Priority to MXPA04006039A priority patent/MXPA04006039A/en
Application filed by Quigley Corp filed Critical Quigley Corp
Priority to IL16250502A priority patent/IL162505A0/en
Priority to NZ533439A priority patent/NZ533439A/en
Publication of WO2003053336A2 publication Critical patent/WO2003053336A2/en
Publication of WO2003053336A3 publication Critical patent/WO2003053336A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)

Abstract

Compositions and methods for the treatment of peripheral neural and vascular ailments are disclosed. The method comprises administering a flavonoid compound with antioxidant properties, optionally formulated in a pharmaceutically acceptable carrier. This compound or combination of compounds provides significant, effective relief of the symptoms of peripheral neural or vascular ailments. In addition, the compositions, when used according to the methods of the present invention, do not exhibit the severe side effects of many prior art compositions proposed for treatment of these ailments.
PCT/US2002/035654 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments Ceased WO2003053336A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ533439A NZ533439A (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments using flavonoid compositions
CA002470603A CA2470603A1 (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments
JP2003554096A JP2005518381A (en) 2001-12-19 2002-11-06 Treatment of peripheral nerve and vascular disease
EP02789474A EP1455778A4 (en) 2001-12-19 2002-11-06 METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
MXPA04006039A MXPA04006039A (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments.
AU2002352501A AU2002352501B2 (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments
IL16250502A IL162505A0 (en) 2001-12-19 2002-11-06 Method for treatment of peripheral neural and vascular ailments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/049297 WO2002049575A2 (en) 2000-12-21 2001-12-19 Method and composition for the treatment of diabetic neuropathy
USPCT/US01/49297 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003053336A2 WO2003053336A2 (en) 2003-07-03
WO2003053336A3 true WO2003053336A3 (en) 2003-11-27

Family

ID=21743140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035654 Ceased WO2003053336A2 (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments

Country Status (8)

Country Link
EP (1) EP1455778A4 (en)
JP (1) JP2005518381A (en)
CA (1) CA2470603A1 (en)
IL (1) IL162505A0 (en)
MX (1) MXPA04006039A (en)
NZ (1) NZ533439A (en)
WO (1) WO2003053336A2 (en)
ZA (1) ZA200404614B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273144B2 (en) 2012-03-23 2022-03-15 Epirium Bio Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5044122B2 (en) * 2003-10-24 2012-10-10 株式会社明治 Novel inhibitors of late glycation end product formation and aldose reductase inhibitors
EP1681297A4 (en) * 2003-10-30 2009-06-17 Meiji Seika Kaisha Tyrosinase activity inhibitor and ameliorant for facial blood flow
WO2005046584A2 (en) 2003-11-05 2005-05-26 Osteoscreen, Inc. Stimulation of hair growth by ginkgo biloba flavanoids
JP2006083105A (en) * 2004-09-16 2006-03-30 Ito En Ltd Blood fluidity improver and food and drink
JP2008546845A (en) * 2005-06-28 2008-12-25 ケージーケー シナガイズ インク． Compositions that improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease
DE102005048777A1 (en) * 2005-10-10 2007-04-12 Beiersdorf Ag Cosmetic formulations to improve the microcirculation of the skin
DE102005048778A1 (en) * 2005-10-10 2007-04-12 Beiersdorf Ag Cosmetic formulations to improve the appearance of the skin
JP5132889B2 (en) * 2006-02-27 2013-01-30 株式会社ポッカコーポレーション Nerve growth factor potentiator
CA2648250A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
FR2904557B1 (en) * 2006-08-01 2010-04-30 Pf Medicament NOVEL EUCALYPTUS EXTRACT, PREPARATION METHOD THEREOF AND THERAPEUTIC USES THEREOF
GB0618168D0 (en) * 2006-09-15 2006-10-25 Babraham Inst Compounds
US20090060878A1 (en) * 2007-09-04 2009-03-05 The Procter & Gamble Company Oral Compositions, Products And Methods Of Use
CA2734991A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
JP5415216B2 (en) * 2009-10-02 2014-02-12 日本メナード化粧品株式会社 Topical skin preparation
CN102266320B (en) * 2010-07-20 2015-06-17 浙江养生堂天然药物研究所有限公司 New application of hesperetin
KR101021835B1 (en) 2010-09-06 2011-03-17 충남대학교산학협력단 Composition for the prevention and treatment of heart disease containing chrysosplenol
CN102151281B (en) * 2011-01-24 2014-03-26 中国药科大学 Flavonoid compound for preventing and treating diabetes and medicament application thereof
ES2719266T3 (en) 2011-07-22 2019-07-09 Massachusetts Inst Technology Histone deacetylase class I activators (HDACS), and uses thereof
NZ596015A (en) * 2011-10-26 2014-04-30 Anzamed Internat Ltd Method and composition for the treatment of pain and/or inflammation
CN102526248B (en) * 2012-03-22 2013-07-17 赵海潞 Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar
EP2827856A4 (en) * 2012-03-23 2016-03-09 Cardero Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISORDERS
ITRM20120335A1 (en) * 2012-07-13 2014-01-14 Aboca Spa Societa Agricola NEW COMPOSITIONS FOR NEUROPATHIC PAIN TREATMENT.
WO2014095289A2 (en) * 2012-12-20 2014-06-26 Unilever Plc Method of treating hair ageing
HK1221611A1 (en) 2013-03-15 2017-06-09 Abbott Laboratories Methods of maintaining and improving muscle function
CN104547872A (en) * 2015-01-30 2015-04-29 山东省立医院 Traditional Chinese medicine composition for treating epilepsy
CN107126437A (en) * 2016-02-29 2017-09-05 上海中医药大学 A kind of medicinal usage of Sophoricoside
KR101828379B1 (en) 2016-03-30 2018-02-12 우석대학교 산학협력단 Compositions for the improvement of memory and cognition ability, or prevention, delay, improvement or treatment of Alzheimer's disease comprising Rosa rugosa THUNB flower extracts or fractions
KR101715294B1 (en) * 2016-06-09 2017-03-10 연세대학교 산학협력단 Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising diosmin or salt thereof
WO2018078412A1 (en) * 2016-10-31 2018-05-03 Posi Visionary Solutions Llp Topical microemulsion of diosmetin and uses thereof
CN108164489B (en) * 2018-03-20 2019-11-26 武汉轻工大学 A kind of preparation method of Galangin
BR102018005599A2 (en) * 2018-03-21 2019-10-08 Pedro Barboza Da Rocha HAZARDOUS, HYDRATING, MOISTURIZING AND EMOLIENT COMPOSITION FOR TOPIC ADMINISTRATION IN INTERTRIGO SKIN INJURIES, SKIN INJURY AND FECAL INJURY AND OTHER RELATED INJURY.
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
CN112014480B (en) * 2019-05-28 2023-03-28 黄河科技学院 Method for detecting content of effective components in Jiangzhining granules by UPLC-MS/MS
JP7642212B2 (en) * 2020-02-18 2025-03-10 国立大学法人 筑波大学 Composition for regulating neural function
WO2022157381A1 (en) * 2021-01-25 2022-07-28 Universiteit Hasselt Phloretin for use in the treatment of neurodegenerative and demyelinating diseases
CN115317497A (en) * 2022-01-13 2022-11-11 宁夏医科大学 Use of liquiritin in the preparation of thoracic aortic vasodilator drugs
CN114392256B (en) * 2022-02-22 2023-05-09 中山大学附属第八医院（深圳福田） Application of cyanidin in prevention and treatment of vascular calcification
CN120752034A (en) * 2022-11-23 2025-10-03 布莱特西德公司 Compositions and methods for regulating sleep and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03232851A (en) * 1989-12-26 1991-10-16 Nippon Flour Mills Co Ltd Aldose reductase inhibitor
JPH09235284A (en) * 1995-02-23 1997-09-09 Nissan Chem Ind Ltd Indole-type thiazolidine compound
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
IT1302307B1 (en) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
JP4497566B2 (en) * 1998-09-02 2010-07-07 株式会社 日本薬用食品研究所 Aldose reductase inhibitors and novel saponins and novel sapogenols
CN1436074A (en) * 2000-04-11 2003-08-13 宝生物工程株式会社 Remedies
NZ526041A (en) * 2000-12-21 2005-01-28 The Quigley Corp Method and composition for the treatment of diabetic neuropathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] INSTITUTE RESEARCH, (ST. CROIX, MINN. USA); September 2001 (2001-09-01), MCKENNA ET AL.: "Efficacy, safety and use of ginkgo biloba in clinical and preclinicals applications", XP002968525, Database accession no. 2001518690 *
DATABASE MEDLINE [online] ROYAL FREE UNIVERSITY COLLEGE MEDICAL SCHOOL; 2000, SMITH P.D. ET AL.: "MICRONIZED purified flavonoid and the treatment of chronic venous insufficiency: MICROCIRCULATORY mechanisms", XP002968526, Database accession no. 2001153006 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273144B2 (en) 2012-03-23 2022-03-15 Epirium Bio Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders

Also Published As

Publication number Publication date
ZA200404614B (en) 2005-08-29
IL162505A0 (en) 2005-11-20
AU2002352501A1 (en) 2003-07-09
EP1455778A4 (en) 2007-09-12
CA2470603A1 (en) 2003-07-03
EP1455778A2 (en) 2004-09-15
NZ533439A (en) 2006-06-30
JP2005518381A (en) 2005-06-23
WO2003053336A2 (en) 2003-07-03
MXPA04006039A (en) 2004-09-27

Similar Documents

Publication Publication Date Title
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2002085303A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2427227A1 (en) Lactam compound
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
WO2005032493A3 (en) Amide compounds as ion channel ligands and uses thereof
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2004005286A3 (en) Viral inhibitors
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004108062A3 (en) Prophylaxis and/or treatment of portal hypertension
WO2000078296A3 (en) Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002352501

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002789474

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/04614

Country of ref document: ZA

Ref document number: 533439

Country of ref document: NZ

Ref document number: 200404614

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 162505

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1683/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2470603

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006039

Country of ref document: MX

Ref document number: 2003554096

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002789474

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002352501

Country of ref document: AU